miR-363 Confers Taxane Resistance in Ovarian Cancer by Targeting the Hippo Pathway Member, LATS2

Oncotarget - United States
doi 10.18632/oncotarget.25698
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Downregulation of MYPT1 Increases Tumor Resistance in Ovarian Cancer by Targeting the Hippo Pathway and Increasing the Stemness

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2020English

Dysregulation of miR-106a and miR-591 Confers Paclitaxel Resistance to Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

TNFAIP8 Promotes Cell Growth by Regulating the Hippo Pathway in Epithelial Ovarian Cancer

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2019English

MS31.03 Targeting the Hippo Pathway

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting the AXL Signaling Pathway in Ovarian Cancer

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2016English

The Hippo Pathway Transcriptional Co-Activator, YAP, Confers Resistance to Cisplatin in Human Oral Squamous Cell Carcinoma

International Journal of Oncology
Cancer ResearchOncology
2015English

circRNA_0000140 Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting miR-31 to Inhibit Hippo Signaling Pathway

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2020English

Reversing Platinum Resistance in Ovarian Cancer Multicellular Spheroids by Targeting BCL-2

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy